{"id":"W2908639608","doi":"10.1016/j.ygyno.2018.12.009","title":"Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial","year":2019,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"Medac; Clovis Oncology; Russian Science Foundation; Merck KGaA; Teva Pharmaceutical Industries; Genentech; PharmaMar; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Ovarian cancer; Adverse effect; Population; Clinical endpoint; Placebo; Surgery; Anemia; Randomized controlled trial; Confidence interval; Cancer; Oncology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001574166,0.0003772639,0.0009875834,0.0001242575,0.0001445385,0.0004764364,0.0002639508,0.000400275,0.0008594557],"category_scores_gemma":[0.00131522,0.0001153909,0.001084097,0.0001965612,0.0002415182,0.0003428426,0.000231899,0.0006960691,0.0001244812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003124692,"about_ca_system_score_gemma":0.0003510778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003635294,"about_ca_topic_score_gemma":0.0009290816,"domain_scores_codex":[0.9996597,0.000169308,0.00003170281,0.00005452154,0.00004724237,0.00003757815],"domain_scores_gemma":[0.9992608,0.0001515508,0.0003017411,0.00004251732,0.00003841205,0.0002050451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7256991,0.002951475,0.09695327,0.001981512,0.005557954,0.0003187323,0.0002040843,0.001439576,0.01169047,0.0001903625,0.002446134,0.1505675],"study_design_scores_gemma":[0.3635631,0.1718864,0.4415477,0.0005634889,0.006699037,0.001513978,0.000155395,0.001784236,0.002299701,0.0004868195,0.009419882,0.00008030798],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850377,0.01346965,0.00008643087,0.0001571152,0.00005671503,0.0001207462,0.0003618395,0.000009384744,0.0007004557],"genre_scores_gemma":[0.9927648,0.004797607,0.000222128,0.000325669,0.0001620694,0.0001321526,0.001238025,0.000004586755,0.0003530728],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001574166,"threshold_uncertainty_score":0.00832504,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02799214301805251,"score_gpt":0.3271328342064086,"score_spread":0.2991406911883561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}